Abstract
Extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) occur frequently and may present themselves before or after IBD diagnosis. They most commonly affect the eyes, skin, and joints, but can also involve other organs such as the liver. Some EIM are associated with intestinal disease activity and ameliorate by treatment of the underlying IBD. This is seen in patients with peripheral Type 1 arthritis, oral aphthous ulcers, episcleritis, and erythema nodosum. Other EIM are intestinal disease activity-independent such as uveitis, and ankylosing spondylitis. Finally, some EIM (e.g. pyoderma gangrenosum and primary sclerosing cholangitis) may or may not be associated with the underlying IBD. Successful therapy of EIM is important for improving quality of life of IBD patients. TNF antibody therapy is an important treatment option for EIM in IBD patients whereas no such beneficial effect was reported for alpha 4 beta 7 integrin antibodies such as vedolizumab so far. This article reviews the therapeutic experience with TNF antibodies for the treatment of EIM in IBD patients.
Keywords: Arthritis, extraintestinal manifestations, inflammatory bowel disease, uveitis.
Current Drug Targets
Title:Biologics for Extraintestinal Manifestations of IBD
Volume: 15 Issue: 11
Author(s): Stephan R. Vavricka, Michael Scharl, Martin Gubler and Gerhard Rogler
Affiliation:
Keywords: Arthritis, extraintestinal manifestations, inflammatory bowel disease, uveitis.
Abstract: Extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) occur frequently and may present themselves before or after IBD diagnosis. They most commonly affect the eyes, skin, and joints, but can also involve other organs such as the liver. Some EIM are associated with intestinal disease activity and ameliorate by treatment of the underlying IBD. This is seen in patients with peripheral Type 1 arthritis, oral aphthous ulcers, episcleritis, and erythema nodosum. Other EIM are intestinal disease activity-independent such as uveitis, and ankylosing spondylitis. Finally, some EIM (e.g. pyoderma gangrenosum and primary sclerosing cholangitis) may or may not be associated with the underlying IBD. Successful therapy of EIM is important for improving quality of life of IBD patients. TNF antibody therapy is an important treatment option for EIM in IBD patients whereas no such beneficial effect was reported for alpha 4 beta 7 integrin antibodies such as vedolizumab so far. This article reviews the therapeutic experience with TNF antibodies for the treatment of EIM in IBD patients.
Export Options
About this article
Cite this article as:
Vavricka R. Stephan, Scharl Michael, Gubler Martin and Rogler Gerhard, Biologics for Extraintestinal Manifestations of IBD, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140908125453
DOI https://dx.doi.org/10.2174/1389450115666140908125453 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapies Targeting Innate Immunity for Fighting Inflammation in Atherosclerosis
Current Pharmaceutical Design Computational Simulation of Drug Delivery at Molecular Level
Current Medicinal Chemistry Osteogenic Differentiation Factors of Multipotent Mesenchymal Stromal Cells in the Current Understanding
Current Pharmaceutical Design Use of Anti-Infective Drugs in Rheumatology
Anti-Infective Agents in Medicinal Chemistry Rabbit Models of Ocular Diseases: New Relevance for Classical Approaches
CNS & Neurological Disorders - Drug Targets Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design Cardiovascular Disease in Spondyloarthritides
Current Vascular Pharmacology Treatment of Psoriasis: A Comprehensive Review of Entire Therapies
Current Drug Safety Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety Therapies in Development for Non-Infectious Uveitis
Current Molecular Medicine Treatment of Ankylosing Spondylitis with Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry COX-2 Selective Inhibitors in the Treatment of Arthritis: A Rheumatologist Perspective
Current Topics in Medicinal Chemistry Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design No Association of MicroRNA-146a rs2910164 Polymorphism and Risk of Primary Gout Development in Chinese Han Populations: A Case-control Study
Current Rheumatology Reviews Amidine-Based Bioactive Compounds for the Regulation of Arginine Metabolism
Mini-Reviews in Medicinal Chemistry Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Current Topics in Medicinal Chemistry Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents
Current Pharmaceutical Design Editorial (Thematic Issue: Switching to Biological Agents in Autoimmune and Autoinflammatory Disorders: Current Targets and Therapy)
Current Medicinal Chemistry Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design